Dronabinol for Postoperative Pain
DM
Overseen byDiana Martinez, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase < 1
Waitlist Available
Sponsor: New York State Psychiatric Institute
Approved in 6 Jurisdictions
Trial Summary
What is the purpose of this trial?
This study is designed to investigate the effect of dronabinol on post operative pain in patients undergoing total knee replacement (for their own clinical care).
Research Team
DM
Diana Martinez, MD
Principal Investigator
NYSPI
Eligibility Criteria
Inclusion Criteria
Participants undergoing total knee arthroplasty (TKA) at the CUIMC department of orthopedic surgery as part of their clinical care.
Able to give informed consent and comply with study procedures in English
Exclusion Criteria
Meet DSM-V criteria for current major psychiatric illness, such as bipolar disorder, major depression, or psychosis. Subjects with a current substance use disorder will be excluded. Subjects with a past cannabis use disorder are excluded.
You have a serious medical or neurological condition such as heart disease, low blood pressure, or a neurodegenerative disorder.
You are taking medication that can interfere with the study drug.
Treatment Details
Interventions
- Dronabinol (Cannabinoid)
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: dronabinolExperimental Treatment2 Interventions
active group
Group II: controlPlacebo Group2 Interventions
control group
Find a Clinic Near You
Who Is Running the Clinical Trial?
New York State Psychiatric Institute
Lead Sponsor
Trials
481
Recruited
154,000+
Dr. Elizabeth B. Ford
New York State Psychiatric Institute
Chief Medical Officer since 2023
MD
Dr. Joshua A. Gordon
New York State Psychiatric Institute
Chief Executive Officer
MD, PhD in Neuroscience